The Use of Biosimilars in the Middle East: Review Article
- 87 Downloads
Purpose of Review
Overall, there were 21 separate articles in which the biosimilars were mentioned as integral parts of the reviews and main body of subject. Even these reports have deficiencies in descriptions of types of drugs, Prices, Patient selection strategies and Efficacy studies.
The biosimilar use is still considered a new encounter in the Middle Eastern areas, many countries have never had any experience with their use, With Very little published data in this regard.
We advise the researchers and workers in this Region to pay more attention to documentation and publication of their works and experiences.
KeywordsBiosimilars Intended copies Middle East Arab reigns Guidelines Pharmacovigilance
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.••Farhat F., Othman A., el Karak F., Kattan J. Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region. SpringerPlus. Nature publishing group, 2016;5:2113. https://doi.org/10.1186/s40064-016-3779-8. This article is one of the very few published papers that reflects the Arabic physicians’ knowledge about biosimilars in different specialities.
- 2.Labeling for biosimilar products/guidance for industry, March 2016. [Online]. Available: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
- 3.U.S. Food and Drug Adminstration, 2000. [Online]. Available: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
- 4.Abbreviated new drug application (ANDA): generics, [Online]. Available: https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/default.htm.
- 6.Guideline on similar biological medicinal products, 23 October 2014. [Online]. Available: www.ema.europa.eu/docs/en_GB/document...guideline/2014/.../WC500176768.pdf.
- 7.Informa Life Sciences 3rd annual, 16 march 2015. [Online]. Available: http://www.ieis.org.tr/ieis/assets/media/files/Program.pdf.
- 9.Joseph J, Solonos M, Michaelides M, et al. AB1093 Biosimilar infliximab in rheumatology practice—the Cyprus experience. Ann Rheum Dis. 76:2.Google Scholar
- 10.Egypt issues draft guidelines for biosimilars, Generics and Biosimilars Initiative Online, 2013.Google Scholar
- 11.Biosimilars, [Online]. Available: http://www.eda.mohp.gov.eg/Articles.aspx?id=106.
- 13.Development of Iranian guidelines for ‘biogenerics’. GaBI Online, http://www.gabionline.net/Guidelines/Development-of-Iranian-guidelines-for-biogenerics. Accessed date June 18, 2017.
- 14.Hadavand N.,Valadkhani M. and Zarbakhsh A. Current regulatory and scientific considerations for approving biosimilars in Iran. Egyptian journal of Medical Human Genetics, Elsevier, 27 Aug 2011. www.sciencedirect.com/science/article/pii/S1045105611000844.
- 15.Production of 24 biogeneric products in Iran by 2012, Generic and Biosimilar Initiative Online, 2012. [online]. Available: http://www.gabionline.net/Biosimilars/News/Production-of-24-biogeneric-products-in-Iran-by-2012.
- 17.Kasteng F.,Wilking N. and Jönsson B. Patient access to cancer drugs in nine countries in the Middle East. Semantic scholar. www.semanticscholar.org/paper/Patient-Access-to-Cancer-Drugs-in-Nine-Countries-in-Kasteng-Wilking/2ee6f41defeedec84c1e37714f9eb16e256765fb. Accessed 1 June 2017.
- 18.•Republic of Lebanon Ministry of Public Health. 2015. [Online]. Available: Lebanon Nationamoph.gov.lb/userfiles/files/HealthCareSystem/Pharmaceuticals/LNDI/LNDI-2015.pdf. Accessed March 2, 2017. This PDF carries the guidelines of biosimilar use in Lebanon, one of the few countries to publish such guidance.
- 19.Republic of Lebanon Ministry of Public Health, [Online]. Available: http://www.moph.gov.lb/en/Drugs/index/3/4848/lebanon-national-drug-index-lndi-#/en/Pages/3/3010/pharmaceuticals.
- 20.Akcay E. Turkish approach to bringing biosimilars to market. Medical Regulatory Affairs Today, 2015. http://www.pharmalinkconsulting.com/blog/blog/turkish-approach-to-bringing-biosimilars-to-market/.
- 21.Ministry Of Public Health Suoreme Council of Health, 2015. [Online]. Available: https://d28d0ipak1ih43.cloudfront.net/app/media/13.
- 22.•Ibrahim M.I.M.. Generic medicines policy in Qatar. Generic and Biosimilar Initiative Online 2015;4(1):8 https://doi.org/10.5639/gabij.2015.0401.003. This article gives short notes on the public health trends in Qatar, being one of the wealthiest countries in the region.
- 23.Guidelines on biosimilars., December 2010. [Online]. Available: https://www.sfda.gov.sa/en/drug/news/Documents/DrugMasterFileRequirementsforRegistrationofBiosimi.pdf. Accessed 10 July 2017.
- 24.Lalichan, S. " How to market Generics and Biosimilars in Saudi Arabia". OMICS international, 18 Sept. 2015. www.omicsonline.org/proceedings/how-to-market-generics-and-biosimilars-in-saudi-arabia-33429.html
- 28.AL-Tamimi, Saleh Karamah, et al. “Challenges to Generic Medicines Utilization in Yemeni Healthcare System.” GaBI Journal, 27 Mar. 2013, http://gabi-journal.net/challenges-to-generic-medicines-utilization-in-yemeni-healthcare-system.html. Accessed 21 July 2017.
- 29.Counterfeit drugs: a growing global threat. Lancet 2012 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60289-X/fulltext. Accessed 5 August 2017.